Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson

Last Updated: January 25, 2020

DrugPatentWatch Database Preview

Litigation Details for Genzyme Corporation v. Sandoz, Inc. (D. Maryland 2009)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Genzyme Corporation v. Sandoz, Inc. (D. Maryland 2009)

Docket   Start Trial Date Filed 2009-07-02
Court District Court, D. Maryland Date Terminated 2012-09-28
Cause 35:271 Patent Infringement Assigned To J. Frederick Motz
Jury Demand None Referred To
Patents 5,496,545; 5,667,775; 6,509,013; 6,733,780; 7,014,846; 7,459,151
Attorneys Abby L Lemek; Brandon C Helms; Brian D O Reilly; Charlotte Jacobsen; Christopher Earl Loh; Dennis J McMahon; Donald J Curry; Filko Prugo; Geoffrey H Genth; George E Brown; Jared L Stringham; Jason E O Leary; Jeremy S Snodgrass; M Scotland Morris; Meredith Martin Addy; Robert Brooke Hopkins; Robert L Baechtold; Scott K Reed; Susan Mae Euteneuer; Susanne Flanders; Susanne L Flanders; Thomas J Filarski; Thomas K Hedemann
Firms Axinn Veltrop and Harkrider LLP; Office of Inspector General, U.S. Postal Service
Link to Docket External link to docket
Small Molecule Drugs cited in Genzyme Corporation v. Sandoz, Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for Genzyme Corporation v. Sandoz, Inc. (D. Maryland 2009)

Date Filed Document No. Description Snippet Link To Document
2009-11-23 42 Noninfringement and Invalidity of United States Patent No. 6,733,780. For the reasons set forth in the accompanying… 28 September 2012 1:09-cv-01750-JFM Patent None District Court, D. Maryland External link to document
2009-12-23 49 relates to two patents: U.S. Patent No. 6,773,780 (“’780 patent”) and U.S. Patent No. 5,667,775 (“’775 patent…See id. Appl Prod Patent Patent Drug Substance Drug Product Patent Use Delist No …earliest-expiring patent, the ’663 patent, and filed paragraph IV certifications on two other patents. Id. at 1358…and ’775 patents in the FDA’s Orange Book;2 (2) declining to seek resolution of the ’780 patent but suing…the ’775 patent; (3) refusing a consent judgment that Sandoz does not infringe the’780 patent; and (4) External link to document
2010-01-22 58 listed six patents relating to Renagel® in the Orange Book. Four of these patents, U.S. Patent Nos. 5,496,545…herein as the “2013 patents.” 3 The patent in issue is the same: the „775 patent; and the products…invalid or not infringed „775 patent; the „775 patent is not the “first patent” in the Caraco analysis. …the 2013 patents, meaning it cannot—under any circumstance—enter the market until those patents expire …the 2013 patents; neither Sandoz nor Endo can receive final FDA approval before those patents expire. External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.